Analysis of acute myeloid leukemia incidence and geographic distribution in Canada from 1992 to 2010 reveals disease clusters in Sarnia and other industrial US border cities in Ontario

Cancer
Feras M GhazawiIvan V Litvinov

Abstract

Several risk factors have been implicated in acute myeloid leukemia (AML) leukemogenesis. However, the epidemiologic distribution and precise triggers for AML in Canada remain poorly understood. In this study, demographic data for AML patients in Canada from 1992 to 2010 were analyzed using 3 independent population-based cancer registries. The AML incidence and mortality rates were examined at the levels of province/territory, city, and forward sortation area (FSA) postal code. In total, 18,085 patients were identified. AML incidence was documented to be 30.61 cases per million individuals per year (95% confidence interval [CI], 30.17-31.06) from 1992 to 2010. Five industrial cities in Ontario were identified where incidence rates were significantly higher than the national average: Sarnia, Sault Ste. Marie, Thunder Bay, St. Catharines, and Hamilton. Analysis at the FSA postal code level identified significant patient clusters of AML in these cities. Specifically, FSA N7V in Sarnia, Ontario had an incidence of 106.81 (95% CI, 70.96-161.86) cases per million individuals per year, which is >3 times higher than the national average. The pollution from local oil refineries and chemical plants in Sarnia may be implicated as a risk f...Continue Reading

References

Nov 4, 1992·Journal of the National Cancer Institute·J A TaylorE Liu
Nov 28, 2006·Lancet·Elihu Estey, Hartmut Döhner
Mar 17, 2007·Pediatric Blood & Cancer·Brenda R ClarkJohn R Wilkins
May 20, 2009·Cancer·Shabbir M H AlibhaiJoseph Brandwein
Jan 8, 2010·International Journal of Environmental Research and Public Health·Dominic Odwa AtariKaren Fung
Oct 11, 2011·Pediatric Hematology and Oncology·Ketan KulkarniRhonda J Rosychuk
Jun 26, 2012·Journal of Cancer Education : the Official Journal of the American Association for Cancer Education·Catherine M SandersGeorgia Robins Sadler
May 7, 2013·Cancer Epidemiology·Jessica R B MusselmanJulie A Ross
Feb 28, 2015·Current Protocols in Mouse Biology·Claire L Dent, Anthony R Isles
Jan 16, 2016·Blood Cancer Journal·F StölzelG Ehninger
Feb 7, 2016·Jornal de pediatria·Mariana Cardoso de LimaMaurício Laerte Silva
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Aug 5, 2017·BMC Public Health·Andrea Christine ShyshFariborz Rashid-Kolvear
Dec 16, 2017·Journal of Cutaneous Medicine and Surgery·Feras M GhazawiIvan V Litvinov
Jan 13, 2018·Scientific Reports·Yinjun ZhaoShuangge Ma
Aug 10, 2018·Journal of the American Academy of Dermatology·Feras M GhazawiIvan V Litvinov

❮ Previous
Next ❯

Citations

May 28, 2019·Journal of Cutaneous Medicine and Surgery·Feras M GhazawiIvan V Litvinov
Dec 25, 2019·Cancer·Feras M GhazawiIvan V Litvinov
May 13, 2019·The British Journal of Ophthalmology·Feras M GhazawiIvan V Litvinov
Nov 15, 2019·Journal of Cutaneous Medicine and Surgery·François LagacéIvan V Litvinov
Apr 3, 2020·Journal of Cutaneous Medicine and Surgery·Feras M GhazawiIvan V Litvinov
Nov 15, 2019·The British Journal of Ophthalmology·Rami DarwichIvan V Litvinov
Sep 6, 2019·Breast Cancer Research and Treatment·François LagacéIvan V Litvinov
Jan 18, 2020·The British Journal of Ophthalmology·Rami DarwichIvan V Litvinov
Apr 18, 2020·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Jonathan SimkinGina Ogilvie
Apr 18, 2021·HPB : the Official Journal of the International Hepato Pancreato Biliary Association·Yasi XiaoIvan V Litvinov
Jun 3, 2021·Current Oncology·Leila CattelanElena Netchiporouk
Jul 29, 2021·Journal of Cutaneous Medicine and Surgery·Santina ConteIvan V Litvinov

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.